CD38 and Miyoshi myopathy: Belantamab mafodotin has recently been approved by the U.S. Food and Drug Administration and the European Medicines Agency as a monotherapy for patients with relapsed or refractory MM who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.